Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paula Rodriguez-Otero

Showing results (21-30 of 78) with videos related to

Pageof 8
Sort By:
International Journal of Molecular Sciences|September 9, 2022
<sup>11</sup>C-Methionine PET/CT in Assessment of Multiple Myeloma Patients: Comparison to <sup>18</sup>F-FDG PET/CT and Prognostic ValueMaria I Morales-Lozano, Paula Rodriguez-Otero, Lidia Sancho, et al.
Transplantation|September 25, 2012
Increased infection rate after preemptive rituximab treatment for Epstein-Barr virus reactivation after allogeneic hematopoietic stem-cell transplantationAnna D Petropoulou, Raphael Porcher, Regis Peffault de Latour, et al.
Blood|December 6, 2014
Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumabRégis Peffault de Latour, Véronique Fremeaux-Bacchi, Raphaël Porcher, et al.
Blood Cancer Journal|February 2, 2024
GPRC5D as a novel target for the treatment of multiple myeloma: a narrative reviewPaula Rodriguez-Otero, Niels W C J van de Donk, Kodandaram Pillarisetti, et al.
Blood Cancer Journal|June 19, 2021
KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myelomaSundar Jagannath, Yi Lin, Hartmut Goldschmidt, et al.
Blood|May 23, 2019
Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myelomaAjai Chari, Joaquín Martinez-Lopez, María-Victoria Mateos, et al.
Cancer Medicine|July 28, 2025
Real-World Treatment Patterns and Outcomes in Patients With Relapsed/Refractory Multiple Myeloma and 1-3 Prior Lines of Therapy: Optum DatabaseBinod Dhakal, Hermann Einsele, Jordan M Schecter, et al.
Hematological Oncology|July 6, 2022
Network meta-analysis of randomized trials in multiple myeloma: Efficacy and safety in frontline therapy for patients not eligible for transplantCirino Botta, Emilia Gigliotta, Bruno Paiva, et al.
Haematologica|December 20, 2011
Long-term follow up after allogeneic stem cell transplantation in patients with severe aplastic anemia after cyclophosphamide plus antithymocyte globulin conditioningJohanna Konopacki, Raphaël Porcher, Marie Robin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 30, 2019
The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple MyelomaLaura Moreno, Cristina Perez, Aintzane Zabaleta, et al.
Pageof 8

Showing results (21-30 of 78) with videos related to

Sort By:
Pageof 8
International Journal of Molecular Sciences|September 9, 2022
<sup>11</sup>C-Methionine PET/CT in Assessment of Multiple Myeloma Patients: Comparison to <sup>18</sup>F-FDG PET/CT and Prognostic ValueMaria I Morales-Lozano, Paula Rodriguez-Otero, Lidia Sancho, et al.
Transplantation|September 25, 2012
Increased infection rate after preemptive rituximab treatment for Epstein-Barr virus reactivation after allogeneic hematopoietic stem-cell transplantationAnna D Petropoulou, Raphael Porcher, Regis Peffault de Latour, et al.
Blood|December 6, 2014
Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumabRégis Peffault de Latour, Véronique Fremeaux-Bacchi, Raphaël Porcher, et al.
Blood Cancer Journal|February 2, 2024
GPRC5D as a novel target for the treatment of multiple myeloma: a narrative reviewPaula Rodriguez-Otero, Niels W C J van de Donk, Kodandaram Pillarisetti, et al.
Blood Cancer Journal|June 19, 2021
KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myelomaSundar Jagannath, Yi Lin, Hartmut Goldschmidt, et al.
Blood|May 23, 2019
Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myelomaAjai Chari, Joaquín Martinez-Lopez, María-Victoria Mateos, et al.
Cancer Medicine|July 28, 2025
Real-World Treatment Patterns and Outcomes in Patients With Relapsed/Refractory Multiple Myeloma and 1-3 Prior Lines of Therapy: Optum DatabaseBinod Dhakal, Hermann Einsele, Jordan M Schecter, et al.
Hematological Oncology|July 6, 2022
Network meta-analysis of randomized trials in multiple myeloma: Efficacy and safety in frontline therapy for patients not eligible for transplantCirino Botta, Emilia Gigliotta, Bruno Paiva, et al.
Haematologica|December 20, 2011
Long-term follow up after allogeneic stem cell transplantation in patients with severe aplastic anemia after cyclophosphamide plus antithymocyte globulin conditioningJohanna Konopacki, Raphaël Porcher, Marie Robin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 30, 2019
The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple MyelomaLaura Moreno, Cristina Perez, Aintzane Zabaleta, et al.
Pageof 8